BioCentury | May 1, 2020
Distillery Therapeutics

The lipids LXA4 and RvD1 as treatment for E. coli pneumonia

DISEASE CATEGORY: Infectious disease INDICATION: Escherichia; pneumonia The lipids LXA4 and RvD1, ligands of the membrane receptor FPRL1, could treat E. coli pneumonia by promoting antibacterial functions in neutrophils. The release of neutrophil elastase, induced...
BioCentury | Sep 18, 2019
Distillery Therapeutics

Treating Parkinson's with the resolvin RvD1

DISEASE CATEGORY: Neurology INDICATION: Parkinson's disease (PD) The resolvin RvD1, a metabolite of omega-3 fatty acids, could treat Parkinson’s disease by preventing inflammation in the brain. CSF and plasma levels of RvD1 were lower in...
BioCentury | Jul 25, 2019
Translation in Brief

New Therapeutic Targets and Biomarkers: June 2019

New Therapeutic Targets and Biomarkers: June 2019 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database in June. Therapeutic targets are defined as any protein, gene or other molecule...
BioCentury | Jun 27, 2019
Distillery Therapeutics

Ketorolac and resolvins to prevent cancer recurrence

DISEASE CATEGORY: Cancer INDICATION: Cancer, lung cancer, lymphoma, melanoma, colorectal cancer The generic COX inhibitor ketorolac and/or the resolvins RvD2, RvD3 and RvD4 could help prevent cancer recurrence due to chemotherapy- or surgery-induced inflammation. In...
BioCentury | Dec 5, 2017
Distillery Therapeutics

Cancer

INDICATION: Solid tumors Cell culture and mouse studies suggest RvD1, RvD2 and RvE1 could help treat solid tumors. In a mouse model of lung cancer and a xenograft model of pancreatic cancer, intraperitoneal injection of...
BioCentury | Nov 30, 2017
Preclinical News

Resolvins keep tumor debris from stimulating tumor growth

In an article published in the Journal of Experimental Medicine , researchers at Beth Israel Deaconess Medical Center and colleagues showed that resolvins, a class of lipids, can suppress the pro-cancer activity of tumor debris generated...
BioCentury | Nov 9, 2016
Distillery Therapeutics

Cardiovascular

INDICATION: Atherosclerosis Patient sample and mouse studies suggest RvD1 could help treat atherosclerosis. In carotid artery tissue samples from patients undergoing endarterectomy, levels of RvD1 were lower in unstable atherosclerotic plaques than in stable plaques...
BioCentury | Oct 27, 2016
Distillery Therapeutics

Neurology

INDICATION: Guillain-Barré syndrome (GBS) Mouse studies suggest RvD1 could help treat the acute inflammatory demyelinating polyneuropathy (AIDP) subtype of GBS. In a mouse model of AIDP, intraperitoneal RvD1 decreased demyelination of sciatic nerves and disease...
BioCentury | Sep 3, 2015
Distillery Therapeutics

Therapeutics: Influenza A virus hemagglutinin (HA)

Infectious disease INDICATION: Influenza virus In vitro and mouse studies identified a broadly neutralizing antibody (bNAb) that could help treat influenza or design cross-reactive vaccines. The bNAb targeting the stem region of HA was isolated...
BioCentury | May 31, 2012
Distillery Therapeutics

Indication: Infectious disease

...Infectious disease Bacterial infections Resolvin D1 (RvD1); RvD5 A study in mice suggests RvD1 and RvD5...
...be useful for treating bacterial infections. In a mouse model of bacterial infection, Rvd1 and Rvd5...
...fever and increased survival compared with no treatment. Next steps could include testing RvD1 and RvD5...
Items per page:
1 - 10 of 17